{"url_path":"/sec/xfor/8-k/2026-05-13/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K/A","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1501697/0001501697-26-000051-index.html","accession_number":"0001501697-26-000051","cik":"0001501697","ticker":"XFOR","issuer_name":"X4 Pharmaceuticals, Inc","edgar_url":"https://www.sec.gov/Archives/edgar/data/1501697/0001501697-26-000051-index.html","primary_entity_key":"0001501697","primary_entity_name":"X4 Pharmaceuticals, Inc"},"word_count":275,"has_tables":true,"body_markdown":"Item 5.07.Submission of Matters to a Vote of Security Holders.\n\nThe final results for each of the proposals submitted to a vote of the Company’s stockholders at the Annual Meeting are set forth below. These proposals are described in detail in the Proxy Statement.\n\nProposal 1.Election of the three Class III director nominees to serve until the 2029 Annual Meeting of Stockholders\n\nThe Company’s stockholders elected the persons listed below as director, to serve until the Company’s 2029 Annual Meeting of Stockholders and until their respective successor is duly elected and qualified or until their earlier death, resignation of removal. The votes cast were as follows:\n\nNomineesForWithheldBroker non-votes\n\nGary J. Bridger, Ph.D.72,863,2693,510,1346,474,104\n\nFrançoise De Craecker73,419,3832,954,0206,474,104\n\nMurray W. Stewart, M.D.\n71,679,8344,693,5696,474,104\n\nProposal 2.Ratification of the selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026\n\nThe Company’s stockholders ratified the selection of PricewaterhouseCoopers LLP by the Audit Committee of the Board of Directors as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The votes cast were as follows:\n\nFORABSTAINAGAINSTBROKER NON-VOTES\n\n82,734,67443,84168,992—\n\nProposal 3.Approval of the Second Amended and Restated 2017 Equity Incentive Plan\n\nThe Company’s stockholders approved the Second Amended and Restated 20217 Equity Incentive Plan. The votes cast were as follows:\n\nFORABSTAINAGAINSTBROKER NON-VOTES\n\n58,679,5529,71117,684,1406,474,104\n\nProposal 4.Approval, on a non-binding, advisory basis of the compensation of the Company’s named executive officers\n\nThe Company’s stockholders approved, by a non-binding “say-on-pay” vote, the compensation of the Company’s named executive officers as disclosed in the Company’s definitive proxy statement relating to the Annual Meeting. The votes cast were as follows:\n\nFORABSTAINAGAINSTBROKER NON-VOTES\n\n70,932,14220,6925,420,5696,474,104"}